Atypical femoral fractures: a complication of prolonged bisphosphonate therapy?

Christian M Girgis and Markus J Seibel
Med J Aust 2011; 194 (2): . || doi: 10.5694/j.1326-5377.2011.tb04182.x
Published online: 17 January 2011

In reply: We thank Falkenberg for his comments in reference to our article in the Journal.1 Two recent large-scale population-based studies have suggested that subtrochanteric femur fractures are rare both in the general population and among bisphosphonate users.2,3 While personal experience may often suggest otherwise, a cluster of atypical fractures cannot be used as an indicator of true incidence in the absence of data on the frequency of bisphosphonate use in a particular population.

  • Christian M Girgis
  • Markus J Seibel

  • University of Sydney, Sydney, NSW.


Competing interests:

Markus Seibel is a member of advisory boards for Merck Sharp and Dohme, Novartis, Amgen and Sanofi-Aventis. He has also received funding from these companies for institutional research.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.